Efficacy of Wharton Jelly Mesenchymal Stromal Cells infusions in moderate to severe SARS-Cov-2 related acute respiratory distress syndrome: a phase 2a double-blind randomized controlled trial

Efficacy of Wharton Jelly Mesenchymal Stromal Cells infusions in moderate to severe SARS-Cov-2 related acute respiratory distress syndrome: a phase 2a double-blind randomized controlled trial

BackgroundThe COVID-19 pandemic caused a wave of acute respiratory distress syndrome (ARDS) with a high in-hospital mortality, especially in patients requiring invasive mechanical ventilation. Wharton Jelly-derived Mesenchymal Stromal Cells (WJ-MSCs) may counteract the pulmonary damage induced by th...

Full description

Bibliographic Details
Main Authors: Cécile Pochon, Caroline Laroye, Antoine Kimmoun, Loic Reppel, Adéle Dhuyser, Hélène Rousseau, Mélanie Gauthier, Nadine Petitpain, Jean-François Chabot, Simon Valentin, Marcelo de Carvalho Bittencourt, Michael Peres, Alice Aarnink, Véronique Decot, Danièle Bensoussan, Sébastien Gibot
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-08-01
Series:Frontiers in Medicine
Subjects:
ARDS
COVID-19
mesenchymal stromal cells
intensive care
oxygenation
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2023.1224865/full

Internet

https://www.frontiersin.org/articles/10.3389/fmed.2023.1224865/full

Similar Items